A prospective survey of XXXX in a web registry in Japan.

@entity1 @entity16058 @entity3131 @entity2416 @entity401
BACKGROUND: There have been no prospective large-scale multicenter epidemiological studies on the clinical course and treatment from the time of diagnosis of @entity16058 ( @entity16058 ) in Japan. The purpose of this study was to clarify the current clinical situation of IIP in Japan. METHODS: This study was supported by a grant from the Ministry of Health, Labour and Welfare to the Diffuse Lung Diseases Research Group. Data including clinical findings, course, and treatment of IIP from a web database created by a collaborative effort of medical institutions across Japan that specialize in the care of @entity401 were collected and analyzed. RESULTS: A total of 436 IIP @entity1 from 19 institutions were newly registered during a 5-year period. @entity2416 ( @entity2416 ) was the most frequently encountered IIP, and 28% of the @entity2416 cases were initially diagnosed by abnormal chest X-ray or CT in asymptomatic @entity1 . Until the 2008 fiscal year, no treatment was given for most cases of @entity2416 . After the end of 2008, when @entity3131 was approved for manufacture, the number of @entity1 for whom no treatment was recommended declined, and @entity3131 therapy was initiated in 32.9% of cases in 2009. The median survival times for @entity2416 from the onset symptoms and from the initial visit were 105 months and 69 months, respectively. CONCLUSIONS: This study should provide valuable information for understanding the current state of IIP in Japan.
